The rapid release of trial results for sodium-glucose cotransporter 2 inhibitors (SGLT2i) and emerging indications demonstrate an exciting new treatment option for patients at high cardiovascular risk. Once considered to fall within the purview of endocrinologists and primary care providers, SGLT2i’s are now therapies that cardiac care providers must consider for their ASCVD and HF patients.

Learn more about the FDA indications and novel mechanisms of canagliflozin, dapagliflozin, and empagliflozin, guideline-directed treatments of ASCVD, hypertension, and HF treatment options, and explore the benefits of these therapies for patients with impaired renal function. Throughout this course you’ll gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients.

Certified Patient Cases

Apply your knowledge of SGLT2i’s and their role in CV risk reduction for high risk patients through these certified patient cases.

 
   
Self-Paced Learning

SGLT2i’s Beyond Diabetes: From Trials to Treatment Strategies eLearning curriculum will decipher the wave of new trial evidence and review the novel mechanisms and clinical indications for SGLT2i’s.

 



  
Webinar

Join chair James L. Januzzi Jr, MD, FACC, and expert faculty Alison Bailey, MD, FACC, Michelle M. Kittleson, MD, FACC, Melissa Magwire, CDE, MSN, RN, and Muthiah Vaduganathan, MD for a virtual session to gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients.

 


  
Click here to see additional Spotlight Topics in the Clinical Spotlight Series

We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection:

James L. Januzzi, Jr., MD, FACC

Muthiah Vaduganathan, MD

Alison Bailey, MD, FACC

Michelle M. Kittleson, MD, FACC

Melissa Magwire, CDE, MSN, RN

Emily Lau, MD – (certified patient case author, not involved in the webinar)

Supported by: AstraZeneca and Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
Powered By